Initiation - Spark Newswire

1 minute read

UBS Initiates Coverage On Federal Realty Investment with Neutral Rating, Announces Price Target of $120

Today, 8:50 AM

UBS analyst Michael Goldsmith initiates coverage on Federal Realty Investment (NYSE:FRT) with a Neutral rating and announces Price Target of $120.

FRT

1 minute read

UBS Initiates Coverage On Simon Property Group with Neutral Rating, Announces Price Target of $135

By Benzinga Newsdesk

Today, 8:50 AM

UBS analyst Michael Goldsmith initiates coverage on Simon Property Group (NYSE:SPG) with a Neutral rating and announces Price Target of $135.

SPG

1 minute read

UBS Initiates Coverage On Regency Centers with Neutral Rating, Announces Price Target of $66

By Benzinga Newsdesk

Today, 8:50 AM

UBS initiates coverage on Regency Centers (NASDAQ:REG) with a Neutral rating and announces Price Target of $66.

REG

1 minute read

Goldman Sachs Initiates Coverage On Avantor with Buy Rating, Announces Price Target of $40

By Benzinga Newsdesk

Today, 8:50 AM

Goldman Sachs analyst Matthew Sykes initiates coverage on Avantor (NYSE:AVTR) with a Buy rating and announces Price Target of $40.

AVTR

1 minute read

Goldman Sachs Initiates Coverage On Twist Bioscience with Neutral Rating, Announces Price Target of $110

By Benzinga Newsdesk

Today, 8:50 AM

Goldman Sachs analyst Matthew Sykes initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Neutral rating and announces Price Target of $110.

TWST

1 minute read

Goldman Sachs Initiates Coverage On Quanterix with Sell Rating, Announces Price Target of $53

By Benzinga Newsdesk

Today, 8:50 AM

Goldman Sachs analyst Matthew Sykes initiates coverage on Quanterix (NASDAQ:QTRX) with a Sell rating and announces Price Target of $53.

QTRX

1 minute read

Piper Sandler Initiates Coverage On Shift Technologies with Overweight Rating, Announces Price Target of $14

By Benzinga Newsdesk

Today, 8:50 AM

Piper Sandler analyst Alexander Potter initiates coverage on Shift Technologies (NASDAQ:SFT) with a Overweight rating and announces Price Target of $14.

SFT

1 minute read

Oppenheimer Initiates Coverage On Windtree Therapeutics with Outperform Rating, Announces Price Target of $8

By Benzinga Newsdesk

Today, 8:50 AM

Oppenheimer analyst Leland Gershell initiates coverage on Windtree Therapeutics (NASDAQ:WINT) with a Outperform rating and announces Price Target of $8.

WINT